CLDX

Several key events have impacted Celldex Therapeutics' stock price in the past six months. Celldex announced the early completion of enrollment for its Phase 3 CSU studies in February 2026. In December 2025, Celldex initiated a global Phase 3 study in cold urticaria and symptomatic dermographism. In April 2026, Celldex closed an underwritten public offering, generating gross proceeds of approximately $345 million. On May 7, 2026, Celldex reported its financial results for the first quarter ended March 31, 2026, reporting a net loss of $78.7 million. In April 2026, Barclays upgraded Celldex Therapeutics from "Sell" to "Buy" and raised its price target, Goldman Sachs maintained a "Neutral" rating in March 2026, and Wall Street Zen upgraded Celldex from a "strong sell" to a "sell" rating in May 2026.